Subsys Pushes Insys Therapeutics (INSY) to 3Q Beat; Piper Jaffray Reiterates Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
GTSO: Edibles Recall Highlights Need for Newer, Better Cannabis Solutions
November 5, 2015 8:52 AM ESTSAN JOSE, Calif.--(BUSINESS WIRE)-- As demand grows for greater precautions and regulations in the booming U.S. cannabis industry, products in Colorado were recalled this week due to contamination by potentially harmful pesticides used during cultivation. Green Technology Solutions, Inc. (OTCBB: GTSO) is working to market and develop new technologies to calm consumer anxieties and help avoid such costly recalls in the future.
Almost 30,000 packages of cannabis-infused edibles were recalled voluntarily in Colorado because independent tests found they contained potentially dangerous pesticides that are not approved for use on cannabis... More
Insys Therapeutics Announces Stock Repurchase Program
November 5, 2015 6:52 AM ESTPHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (Nasdaq: INSY) (Insys or the Company) today announced that its Board of Directors has approved the repurchase of up to $50 million of the Company's common stock.
"The Board of Directors and management team believe that shares of Insys stock are an attractive investment opportunity, and we are pleased that Insys strong balance sheet and cash flow enable us to return value to shareholders through a stock repurchase program, said Dr. John Kapoor, Chairman, President and Chief Executive Officer. At the same time, we are continuing to... More
Insys Therapeutics Announces Stock Repurchase Program
November 5, 2015 6:52 AM ESTPHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (Nasdaq: INSY) (Insys or the Company) today announced that its Board of Directors has approved the repurchase of up to $50 million of the Company's common stock.
"The Board of Directors and management team believe that shares of Insys stock are an attractive investment opportunity, and we are pleased that Insys strong balance sheet and cash flow enable us to return value to shareholders through a stock repurchase program, said Dr. John Kapoor, Chairman, President and Chief Executive Officer. At the same time, we are continuing to... More
Insys Therapeutics Announces Senior Management Changes and Appointments
November 5, 2015 6:51 AM ESTMichael Babich Departs as Insys President and CEO
Dr. John N. Kapoor Appointed President and CEO
Daniel Brennan Appointed Executive Vice President and Chief Operating Officer
PHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that Michael L. Babich has stepped down as President and Chief Executive Officer of Insys. The Board of Directors has appointed Dr. John N. Kapoor as President and Chief Executive Officer effective November 4, 2015. Dr. Kapoor will... More
Insys Therapeutics Announces Senior Management Changes and Appointments
November 5, 2015 6:51 AM ESTMichael Babich Departs as Insys President and CEO
Dr. John N. Kapoor Appointed President and CEO
Daniel Brennan Appointed Executive Vice President and Chief Operating Officer
PHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that Michael L. Babich has stepped down as President and Chief Executive Officer of Insys. The Board of Directors has appointed Dr. John N. Kapoor as President and Chief Executive Officer effective November 4, 2015. Dr. Kapoor will... More
Insys Therapeutics Reports Record Third Quarter 2015 Results
November 5, 2015 6:50 AM ESTAnnounces Senior Management Changes and Appointments
Announces Stock Repurchase up to $50 Million
PHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced financial results for the three- and nine-month periods ended September 30, 2015. Highlights of and subsequent to the third quarter of 2015 include:
Quarter Highlights:
Total net revenue increased to $91.3 million compared to $58.3 million for the third quarter of 2014;Revenue from Subsys® (fentanyl sublingual spray) was $91.1 million,... MoreNTRR: Latest Colorado Edibles Recall Underscores Growing Market for Pesticide Alternatives
November 5, 2015 5:00 AM ESTTAMPA, Fla.--(BUSINESS WIRE)-- A recall of cannabis edibles products in Colorado this month underscores a growing demand for alternatives to harsh chemicals used to control pests in the U.S. cannabis industry, and Neutra Corp. (OTCBB: NTRR) is helping to deliver these new solutions to a hungry marketplace.
In the past several days, nearly 30,000 cannabis edibles products were recalled voluntarily by prominent Colorado suppliers after tests confirmed that they contain potentially harmful pesticides that the state recently banned for use on cannabis plants. Its the largest recall of... More
